Page 79 - Memoria FEHH - SEHH 2017

GRUPO ESPAÑOL DE SÍNDROMES MIELODISPLÁSICOS (GESMD)
MEMORIA ANUAL 2017
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. J Clin Oncol. 2017;35(14):1591-7. doi: 10.1200/JCO.2016.71.3271.
• Paviglianiti A, Ruggeri A, Volt F, Sanz G, Milpied N, Furst S, Esquirol A, Arcese W, Picardi A, Ferra C, Ifrah N, Bou- rhis JH, Raj K, von dem Borne PA, Sica S, Menard AL, Bloor A, Kenzey C, Gluckman E, Rocha V. Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies. Br J Haematol. 2017;179(5):790-801.
• Ramos F, Pedro C, Tormo M, de Paz R, Font P, Luño E, Caballero M, Solano F, Almagro M, Xicoy B, Jiménez M.
Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelo- dysplastic syndromes. Results of GlobQoL study. Eur J Cancer Care (Engl). 2017;26(6). doi: 10.1111/ecc.12426.
• Ramos F, Robledo C, Pereira A, Pedro C, Benito R, de Paz R, Del Rey M, Insunza A, Tormo M, Díez-Campelo M, Xicoy B, Salido E, Sánchez-Del-Real J, Arenillas L, Florensa L, Luño E, Del Cañizo C, Sanz GF, Hernández-Rivas JM; Spanish Group for Myelodysplastic Syndromes (GESMD). Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syn- dromes: a prospective study of the Spanish MDS group. Am J Hematol. 2017;92(9):E534-E541.
Presentaciones orales en congresos internacionales
• Nomdedeu M, Tuechler H, Kuendgen A, Solé F, Schanz J, Hildegart B, Grau J, Pereira A, García-Manero G, Sekeres MA, Komrokji RS, List AF, Voso MT, Cazzola M, Sill H, Stauder R, Greenberg P, Germing U, Sanz G, Haase D. Chro- mosomal Aberrations in Therapy-related Myelodysplastic Syndromes - Relations to Primary Disease, Therapy and Prognostic Significance. Ponencia. 14th International Symposium on Myelodysplastic Syndromes. Valencia, 3-6 de mayo de 2017.
• Adema V, Palomo L, Hirsch CM, Przychodzen BP, Laframboise T, Nazha A, Balasubramanian SK, Carraway HE, Seke- res MA, Visconte V, Solé F, Maciejewski JP. Mutational Signature and Clonal Architecture of Low Risk Myelodys- plastic Syndromes with Del(5q). Ponencia. 14th International Symposium on Myelodysplastic Syndromes. Valencia, 3-6 de mayo de 2017. Oral presentation and for the Tito Bastianello Young Investigator Award.
• Palomo L, Ibáñez M, Abáigar M, Vázquez I, Álvarez S, Cabezón M, Tazón-Vega B, Acha P, Benito R, Cervera J, Cigu- dosa JC, Fuster-Tormo F, Hernández Sánchez JM, Larrayoz MJ, Valcárcel D, Zamora L, Sanz G, Calasanz MJ, Solé F, Such E; on behalf of the Spanish Group of MDS (GESMD). Spanish Guidelines for the use of targeted deep sequencing in MDS and CMML. Ponencia. 14th International Symposium on Myelodysplastic Syndromes. Valencia, 3-6 de mayo de 2017.
• Liquori A, Such E, Palomo L, Moreau S, Pedrola L, Sellés J, Neef A, Zúñiga S, Ibáñez M, Company D, Saus A, Acha P, Sanjuán A, Boluda M, De Matteo B, González E, Sanz MA, Solé F, Sanz G, Cervera J. A single Next-Generation Sequencing (NGS) assay for the detection of point mutations and large chromosomal abnormalities in MDS patients. Ponencia. 14th International Symposium on Myelodysplastic Syndromes. Valencia, 3-6 de mayo de 2017.
• Adema V, Balasubramanian SK, Hirsch KM, Przychodzen BP, Phillips JG, Lindner D, Radivoyevitch T, Mukherjee S, Nazha A, Carraway HE, Solé F, Sekeres MA, Visconte V, Maciejewski JP. Novel Therapeutic Targets for DNMT3A Mutant Myeloid Neoplasms. ASH Abstract 2017.
79